Welcome!

News Feed Item

New HIV Treatment Launched by ViiV Healthcare Addresses Multiple Evolving Needs of People Living With HIV in the UK

LONDON, February 3, 2014 /PRNewswire/ --

ViiV Healthcare today launches its first new treatment, the integrase inhibitor, dolutegravir (TIVICAY®) a treatment for human immunodeficiency virus (HIV). It represents a new option for a wide range of people living with HIV, with proven efficacy in people starting treatment and in those who have developed resistance to multiple HIV drugs. Dolutegravir is indicated for use in combination with other antiretroviral agents for the treatment of adults and adolescents over 12 years of age infected with HIV. Most patients prescribed dolutegravir can take it as a convenient once-daily dose; it can be taken with or without food.[1]

Dr Anton Pozniak, HIV Service Director at Chelsea and Westminster Hospital commented, "Every day we face treatment choices in the management of HIV to balance efficacy with tolerability and convenience. As a new treatment alternative, dolutegravir provides us with an option that seems to address these issues and offers a positive treatment choice for both patients and physicians."

The dolutegravir clinical development programme involved more than 2,500 people living with HIV. The trials demonstrated the efficacy of dolutegravir in people at different stages of treatment, including those starting for the first time[2],[3],[4]as well as people who had started treatment and had developed resistance to other HIV medicines.[5],[6]

In people living with HIV and taking treatment for the first time, dolutegravir was shown to be:

  • comparable to another integrase inhibitor, raltegravir.[4]
  • superior to two other commonly prescribed HIV medicines: boosted darunavir and Atripla®.[2],[3]

In people who had been treated with other HIV medicines (not including integrase inhibitors) and had developed resistance, dolutegravir was found to be superior to raltegravir.[5]

For those who had developed resistance to other integrase inhibitors, dolutegravir was highly effective and reduced the amount of virus circulating in the blood to undetectable levels in more than half of people.[6]

Dolutegravir is generally well tolerated; in the clinical trials, fewer people stopped taking dolutegravir because of adverse reactions than those taking the comparator drugs. The most commonly seen side effects were nausea (seen in 15% of people taking dolutegravir), diarrhoea (16%) and headaches (14%).[1]

Dr Andrew Benzie, ViiV Healthcare UK Medical Director, commented, "The launch of dolutegravir is an important step forward in the treatment of people living with HIV in the UK. At ViiV Healthcare, our focus is on delivering advances in treatment and care for people living with HIV and dolutegravir is the first from our pipeline to be approved. We are working with the NHS to ensure that appropriate patients are able to access this treatment as soon as possible."

A recent UK survey conducted by IPSOS Mori* asking people living with HIV and clinicians about their feelings towards treatment showed that treatment effectiveness is the most important attribute for both groups, followed by side effects and then how easy the treatment is to take.

REFERENCES

  1. Tivicay (dolutegravir) Summary of Product Characteristics (SmPC). Available at http://www.viivhealthcare.com/our-medicines.aspx.
  2. Walmsley S, Antela A, Clumeck N et al. N Engl J Med 2013;369:1807-18.
  3. Clotet B et al. European AIDS Clinical Society (EACS), Brussels, 17 October 2013.
  4. Raffi F, Rachlis A, Stellbrink H-J et al. Lancet 2013;381(9868):735-743.
  5. Cahn P, Pozniak AL, Mingrone H et al Lancet 2013;382(9893):700-708.
  6. Nichols G, Lazzarin A, Maggiolo F, et al, on behalf of the VIKING-3 investigators. Poster presented at: 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; June 30-July 3, 2013. Kuala Lumpur, Malaysia. Poster TULBPE19

Notes to editors:

About Tivicay®(dolutegravir)

Tivicay® is the first new treatment delivered by ViiV Healthcare. It was approved by the U.S. FDA in August 2013 and by Health Canada in October 2013. It is a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor. Integrase inhibitors block HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells (T-cells). This step is essential in the HIV replication cycle. Please refer to the full Summary of Product Characteristics for full prescribing information, including contraindications, special warnings and precautions for use.

Regulatory applications are being evaluated in other countries worldwide. Regulatory applications for ViiV Healthcare's developmental single-tablet regimen (STR) combining Tivicay with Kivexa®/Epzicom® (abacavir/lamivudine) were submitted to regulatory authorities in Europe, Canada and the U.S. in October 2013.

About ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV. Shionogi joined as a 10% shareholder in October 2012. The company's aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and new HIV medicines, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit http://www.viivhealthcare.com.

* About the UK survey

Ipsos MORI interviewed a self-selected sample of 50 physicians and 50 nurses who treat patients with HIV and 50 adults aged 18 years and above diagnosed with HIV across Great Britain. Interviews were conducted online between 4th November and 18th December 2013. Respondents were drawn from healthcare specific market research panels. Data are unweighted and due to the small sample sizes, can only be considered as indicative rather than representative of the population.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"We host and fully manage cloud data services, whether we store, the data, move the data, or run analytics on the data," stated Kamal Shannak, Senior Development Manager, Cloud Data Services, IBM, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
As organizations shift towards IT-as-a-service models, the need for managing and protecting data residing across physical, virtual, and now cloud environments grows with it. Commvault can ensure protection, access and E-Discovery of your data – whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise. In his general session at 18th Cloud Expo, Randy De Meno, Chief Technologist - Windows Products and Microsoft Part...
In addition to all the benefits, IoT is also bringing new kind of customer experience challenges - cars that unlock themselves, thermostats turning houses into saunas and baby video monitors broadcasting over the internet. This list can only increase because while IoT services should be intuitive and simple to use, the delivery ecosystem is a myriad of potential problems as IoT explodes complexity. So finding a performance issue is like finding the proverbial needle in the haystack.
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
With over 720 million Internet users and 40–50% CAGR, the Chinese Cloud Computing market has been booming. When talking about cloud computing, what are the Chinese users of cloud thinking about? What is the most powerful force that can push them to make the buying decision? How to tap into them? In his session at 18th Cloud Expo, Yu Hao, CEO and co-founder of SpeedyCloud, answered these questions and discussed the results of SpeedyCloud’s survey.
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and shared the must-have mindsets for removing complexity from the develo...
SYS-CON Events announced today that MangoApps will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. MangoApps provides modern company intranets and team collaboration software, allowing workers to stay connected and productive from anywhere in the world and from any device.
“We're a global managed hosting provider. Our core customer set is a U.S.-based customer that is looking to go global,” explained Adam Rogers, Managing Director at ANEXIA, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
DevOps at Cloud Expo – being held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real results. Am...
Basho Technologies has announced the latest release of Basho Riak TS, version 1.3. Riak TS is an enterprise-grade NoSQL database optimized for Internet of Things (IoT). The open source version enables developers to download the software for free and use it in production as well as make contributions to the code and develop applications around Riak TS. Enhancements to Riak TS make it quick, easy and cost-effective to spin up an instance to test new ideas and build IoT applications. In addition to...
The 19th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportuni...
"This week we're really focusing on scalability, asset preservation and how do you back up to the cloud and in the cloud with object storage, which is really a new way of attacking dealing with your file, your blocked data, where you put it and how you access it," stated Jeff Greenwald, Senior Director of Market Development at HGST, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
"We've discovered that after shows 80% if leads that people get, 80% of the conversations end up on the show floor, meaning people forget about it, people forget who they talk to, people forget that there are actual business opportunities to be had here so we try to help out and keep the conversations going," explained Jeff Mesnik, Founder and President of ContentMX, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
"When you think about the data center today, there's constant evolution, The evolution of the data center and the needs of the consumer of technology change, and they change constantly," stated Matt Kalmenson, VP of Sales, Service and Cloud Providers at Veeam Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.